Ratnakar Securities

Mobile Trading
COMPANY
more from company profile
HomeMarket Info Company Profile Smart Quotes

Smart Quotes

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE1965.75-8.4 (-0.43 %)
PREV CLOSE ( ) 1974.15
OPEN PRICE ( ) 1966.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 20285
TODAY'S LOW / HIGH ( )1958.35 1988.50
52 WK LOW / HIGH ( )1274.7 2286.15
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 18-11 1977
Management Info
Glenn Saldanha - Chairman Glenn Saldanha - Managing Director
Registered Office

Address B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, ,
Mumbai,
Maharashtra-400026

Phone

Email complianceofficer@glenmarkpharma.com

Website www.glenmarkpharma.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
 Listing : BSE, NSE
NEWS
01Dec USFDA completes Pre-Approval Inspectio
United States Food & Drug Administration (USFDA) has completed Pre-A..
01Dec Glenmark Pharmaceuticals informs about
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclos..
27Nov Glenmark Pharmaceuticals gets EIR with
Glenmark Pharmaceuticals has received Establishment Inspection Report (E..
27Nov Glenmark Pharmaceuticals informs abou
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclos..
27Nov Glenmark Pharmaceuticals soars on gett
Glenmark Pharmaceuticals is currently trading at Rs. 1941.90, up by 20.9..
MORE
Financials
in Millions
QTR Sep 25 ANNUAL 25
Net Profit-7391.8916103.5
Gross Profit -9063.66 21540.18
Operating Profit 1077.5826005.46
Net Sales 15386.692264.09
MORE
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Alkem Laboratories (BSE)
up  5689.30 (1.38%)
M.Cap ( in Cr)68024.12
Abbott India (BSE)
up  28869.35 (0.15%)
M.Cap ( in Cr)61345.35
Glaxosmithkline Phar (BSE)
up  2543.10 (1.35%)
M.Cap ( in Cr)43081.65
Wockhardt (BSE)
up  1360.10 (2.16%)
M.Cap ( in Cr)22100.56
RPG Life Sciences (BSE)
up  2228.80 (1.27%)
M.Cap ( in Cr)3686.22
MORE
Shareholding Pattern
PROMOTERS 46.65%
MUTUAL FUNDS/UTI 16.31%
NON-INSTITUTION 13.97%
FI/BANKS/INSURANCE 0.68%
GOVERNMENT 0.04%
FII 0%
MORE
Mf Holdings
MORE
FAQs
079-49005200 / 01 / 02
info@ratnakarsecurities.com
Download Mobile App

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER
products
about us
usefull links
news room

Ratnakar Securities Pvt. Ltd. : SEBI Registration No. of NSE, BSE : INZ000191735 | SEBI Registration No. of NSDL : IN-DP-NSDL-66-88
Ratnakar Commodities Pvt. Ltd : SEBI Registration No. of MCX : INZ000024138
Investor Grievance ID : investorgrievance@ratnakarsecurities.com
Online Dispute Resolution Portal - SMART ODR
To File A Complaint on SCORES Click Here
For Nomination, Please Click Here
To Close Account, Please Click Here
© 2018 Ratnakar Securities Pvt. Ltd. All rights reserved.
Designed, Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.
CLOSE X

Filing complaints on SCORES Easy & quick

  • > Register on SCORES portal (link:https://scores.gov.in)
  • > Mandatory details for filing complaints on SCORES
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • > Benefits:
    • Effective communication
    • Speedy redressal of the grievances
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.